FEATURED INSIGHTS
INSIGHTS
COVID Vaccine Distribution: A four-phase plan
Pfizer, in cooperation with German-based BioNTech, crossed an historic milestone this week when they submitted to the Food and Drug Administration an emergency use authorization (EUA) for a COVID-19 vaccine. The data will quickly be analyzed by FDA and then submitted to an independent advisory panel in early December for approval, which then also will receive a necessary ‘green light’ from the Centers for Disease Control, particularly regarding the rollout process for Pfizer/BioNTech’s vaccine on a prioritization scale. Read more…
Oxford Vaccine Progress
AstraZeneca is now reporting its AZD1222 COVID-19 mRNA vaccine could be available as early as January of next year. Long favored in the epidemiological community as one of the more likely effective and safe vaccines in development by several major pharmaceutical companies, AstraZeneca’s teaming with Oxford University is now in late-stage trials in Britain and the U.S., as well as other countries, to determine the vaccine’s efficacy and safety.
Vaccines Progress, FDA Approves Useless Treatment
There is good news out of Oxford, which said that the vaccine it developed with Astra Zeneca worked well and triggered a robust immune response in volunteers. Despite the good news, the UK government is warning that a widespread rollout of a coronavirus vaccine is unlikely before Christmas. The government added that the possibility of wider spread use of vaccines isn't going to happen until the spring of next year at the earliest. We would have enough doses and enough understanding of the medical infrastructure to distribute them effectively by that time.
Transparent COVID Vaccine Key to Public Confidence
There is little question in the scientific community now that Pfizer and Moderna are the two most likely companies to develop viable vaccines — at least at this juncture.
COVID STRATEGY GUIDE: Two Races - Vaccines & the Election
We have learned that a safe, effective vaccine against COVID-19, the infection caused by the coronavirus, most likely won’t be available for large segments of the world’s population until 2022 at the earliest.